STOCK TITAN

Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Independent proxy advisory firm ISS recommends shareholders support Sarah Schlesinger for the board of Alkermes plc. They advise withholding support from cancer specialist Richard Gaynor due to an upcoming oncology spin. Sarissa Capital Management issues a presentation advocating for shareholder representation. Shareholders are urged to vote in favor of Sarissa Nominees and against executive compensation. Contact D.F. King & Co., Inc. for assistance with voting.
Positive
  • ISS recommends supporting Sarah Schlesinger for the board
  • Sarissa Capital advocates for shareholder representation
  • Shareholders urged to vote for Sarissa Nominees and against executive compensation
Negative
  • No negative takes identified

Independent proxy advisory firm ISS recognizes the qualifications of Sarissa nominees and advises shareholders to support Sarah Schlesinger

In light of upcoming oncology spin, ISS recommends that shareholders withhold support from cancer specialist Richard Gaynor

GREENWICH, Conn.--(BUSINESS WIRE)-- Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:

Presentation: https://upgradealkermes.com/pr062623

For additional information please visit our website at upgradealkermes.com.
#UpgradeAlkermes

If you have any questions regarding your BLUE universal proxy card or need assistance in executing your proxy card, please contact:

D.F. King & Co., Inc.
Shareholders call Toll-Free: (866) 207-3648
All Others Call: (212) 493-6952
Email: ALKS@dfking.com

Your vote at Alkermes' Annual General Meeting of Shareholders on June 29, 2023 is very important. We urge all shareholders to vote "FOR" the election of the Sarissa Nominees, “AGAINST” the compensation of the Company’s named executive officers, and "FOR" all other proposals in our proxy statement.

You can vote in one of three easy ways: by internet at www.cesvote.com, by telephone at 1-888-693-8683 or by mail using the BLUE universal proxy card and postage-paid envelope sent to you.

If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.

Additional Information

Sarissa Capital Management LP (“Sarissa Capital”), together with other participants, filed a definitive proxy statement and an accompanying BLUE universal proxy card with the SEC on June 2, 2023, in connection with the solicitation of shareholders of the Company for the 2023 annual general meeting of shareholders (the “Annual Meeting”). Shareholders are advised to read the definitive proxy statement and other documents related to the Annual Meeting as they contain important information.

The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov. The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (866) 207-3648).

Dayna Packes

Sarissa Capital Management LP

info@sarissacap.com

Source: Sarissa Capital Management LP

FAQ

Who does ISS recommend for the board of Alkermes plc?

ISS recommends supporting Sarah Schlesinger for the board.

Who should shareholders withhold support from?

Shareholders should withhold support from cancer specialist Richard Gaynor due to an upcoming oncology spin.

What does Sarissa Capital advocate for?

Sarissa Capital advocates for shareholder representation.

What should shareholders vote for and against?

Shareholders should vote for Sarissa Nominees and against executive compensation.

Who should shareholders contact for voting assistance?

Shareholders should contact D.F. King & Co., Inc. for assistance with voting.

Alkermes Inc. plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

4.04B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 4

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.